Zai Lab Limited (ZLAB)
| Market Cap | 2.70B -15.8% |
| Revenue (ttm) | 449.61M +5.1% |
| Net Income | -188.21M |
| EPS | -0.17 |
| Shares Out | 112.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,610,117 |
| Open | 23.19 |
| Previous Close | 22.04 |
| Day's Range | 22.23 - 24.54 |
| 52-Week Range | 15.96 - 28.75 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 33.14 (+37.91%) |
| Earnings Date | Nov 5, 2026 |
About ZLAB
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price target is $33.14, which is an increase of 37.91% from the latest price.
News
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Zai Lab NASDAQ: ZLAB presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with or...
Zai Lab Transcript: Investor update
Zoci plus atezolizumab showed an 81.8% confirmed ORR and 81.9% 6-month PFS at 1.6 mg/kg in first-line SCLC, with encouraging tolerability. A frontline Phase III doublet study is targeted to start by year-end 2026.
Zai Lab Press release: Investor update
Zai Lab issued a press release on October 23, 2026, disclosing material business information to investors.
Zai Lab Slides: Investor update
Zai Lab has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Zai Lab reports results from Phase 1b trial of zocilurtatug pelitecan
Zai Lab (ZLAB) shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan in combination with atezolizumab with and without carboplatin as first-line treatment for e...
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical tr...
Zai Lab announces $250M private placement
Zai Lab (ZLAB) Limited announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares, each representing ten ordinary shares of the Company,…
Zai Lab Announces $250 Million Private Placement
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase ...
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate updat...
Zai Lab management to meet with Cantor
Group Dinner Meeting with Management to be held in Madrid on October 23 hosted by Cantor.
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company's internally developed ...
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-131...
Zai Lab price target raised to $36 from $27 at JPMorgan
JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $36 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first…
Z.ai shares surge 8% after releasing new AI model running only on Chinese chips
Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
Zai Lab (ZLAB) CFO Yajing Chen Sells 260 Shares, Insider Selling Trend Persists
Zai Lab (ZLAB) CFO Yajing Chen Sells 260 Shares, Insider Selling Trend Persists
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Pha...
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript
Zoci advances toward global registrational trials as net product revenue rises 11%.
Zai Lab Q2 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a glob...
Zai Lab price target raised to $45 from $44 at Citi
Citi raised the firm’s price target on Zai Lab (ZLAB) to $45 from $44 and keeps a Buy rating on the shares. The Q2 report shows Zai is transitioning from…
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street e...
Zai Lab Earnings Call Transcript: Q2 2026
Net product revenue rose 11% sequentially to $105.8 million, with commercial profitability maintained and a strong cash position of $717.5 million. Pipeline progress includes three registrational oncology programs by year-end and first U.S. regulatory submission expected next year.
Zai Lab Earnings release: Q2 2026
Zai Lab released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zai Lab Quarterly report: Q2 2026
Zai Lab has published its Q2 2026 quarterly earnings report on August 6, 2026.